| Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology RB Verheijen, H Yu, JHM Schellens, JH Beijnen, N Steeghs, ... Clinical Pharmacology & Therapeutics 102 (5), 765-776, 2017 | 271 | 2017 |
| Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets H Yu, N Steeghs, CM Nijenhuis, JHM Schellens, JH Beijnen, ... Clinical pharmacokinetics 53, 305-325, 2014 | 262 | 2014 |
| Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain – A systematic review and meta-analysis MC Gerardsa, RJ Terlou, H Yu, CHW Koks, VEA Gerdes Atherosclerosis 240 (2), 415-423, 2015 | 200 | 2015 |
| Cellular polyamines promote amyloid-beta (Aβ) peptide fibrillation and modulate the aggregation pathways J Luo, CH Yu, H Yu, R Borstnar, SCL Kamerlin, A Gräslund, ... ACS chemical neuroscience 4 (3), 454-462, 2013 | 109 | 2013 |
| Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662 MHM Diekstra, HJ Klümpen, M Lolkema, H Yu, JSL Kloth, H Gelderblom, ... Clinical Pharmacology & Therapeutics 96 (1), 81-89, 2014 | 90 | 2014 |
| Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients H Yu, N van Erp, S Bins, RHJ Mathijssen, JHM Schellens, JH Beijnen, ... Clinical pharmacokinetics 56, 293-303, 2017 | 46 | 2017 |
| Nanolayered chemical modification of silicon surfaces with ionizable surface groups for pH-triggered protein adsorption and release: application to microneedles K van der Maaden, H Yu, K Sliedregt, R Zwier, R Leboux, M Oguri, A Kros, ... Journal of Materials Chemistry B 1 (35), 4466-4477, 2013 | 43 | 2013 |
| Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662 H Yu, N Steeghs, J Kloth, D de Wit, C van Hasselt, N van Erp, J Beijnen, ... British journal of clinical pharmacology 79 (5), 809-19, 2014 | 37 | 2014 |
| First‐pass CYP3A‐mediated metabolism of midazolam in the gut wall and liver in preterm neonates JM Brussee, H Yu, EHJ Krekels, B de Roos, MJE Brill, JN van den Anker, ... CPT: pharmacometrics & systems pharmacology 7 (6), 374-383, 2018 | 36 | 2018 |
| Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study JSL Kloth, HJ Klümpen, H Yu, K Eechoute, CF Samer, BLR Kam, ... Clinical pharmacokinetics 53, 261-269, 2014 | 35 | 2014 |
| Characterization of intestinal and hepatic CYP3A-mediated metabolism of midazolam in children using a physiological population pharmacokinetic modelling approach JM Brussee, H Yu, EHJ Krekels, S Palić, MJE Brill, JS Barrett, ... Pharmaceutical research 35, 1-13, 2018 | 32 | 2018 |
| Parameter optimization toward optimal microneedle-based dermal vaccination K van der Maaden, EM Varypataki, H Yu, S Romeijn, W Jiskoot, ... European Journal of Pharmaceutical Sciences 64, 18-25, 2014 | 29 | 2014 |
| Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients S Bins, ADR Huitema, P Laven, S Bouazzaoui, H Yu, N van Erp, ... Clinical Pharmacokinetics 58, 651-658, 2019 | 28 | 2019 |
| Drugs being eliminated via the same pathway will not always require similar pediatric dose adjustments EAM Calvier, EHJ Krekels, H Yu, PAJ Välitalo, TN Johnson, ... CPT: Pharmacometrics & Systems Pharmacology 7 (3), 175-185, 2018 | 25 | 2018 |
| Population pharmacokinetic–B cell modeling for ofatumumab in patients with relapsing multiple sclerosis H Yu, G Graham, OJ David, JM Kahn, M Savelieva, E Pigeolet, ... CNS drugs 36 (3), 283-300, 2022 | 19 | 2022 |
| Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases S Pan, H Yu, A Surti, I Cheng, SD Marks, PA Brogan, D Eleftheriou, ... British journal of clinical pharmacology 85 (8), 1790-1797, 2019 | 14 | 2019 |
| Translating QT interval prolongation from conscious dogs to humans VFS Dubois, G Smania, H Yu, R Graf, ASY Chain, M Danhof, ... British Journal of Clinical Pharmacology 83 (2), 349-362, 2017 | 13 | 2017 |
| Model‐based evaluation of drug‐induced QT c prolongation for compounds in early development VFS Dubois, H Yu, M Danhof, O Della Pasqua, ... British Journal of Clinical Pharmacology 79 (1), 148-161, 2015 | 11 | 2015 |
| A population pharmacokinetic model of oral docetaxel coadministered with ritonavir to support early clinical development H Yu, JM Janssen, E Sawicki, JGC van Hasselt, VA de Weger, B Nuijen, ... The Journal of Clinical Pharmacology 60 (3), 340-350, 2020 | 9 | 2020 |
| Development of a tumour growth inhibition model to elucidate the effects of ritonavir on intratumoural metabolism and anti-tumour effect of docetaxel in a mouse model for … H Yu, JJMA Hendrikx, S Rottenberg, JHM Schellens, JH Beijnen, ... The AAPS journal 18, 362-371, 2016 | 6 | 2016 |
Wim JiskootLeiden University, Coriolis Pharma在 lacdr.leidenuniv.nl 的电子邮件经过验证
